Nifty
Sensex
:
:
18696.10
62868.50
-116.40 (-0.62%)
-415.69 (-0.66%)

Pharmaceuticals & Drugs - API

Rating :
37/99

BSE: 530239 | NSE: SUVEN

63.25
01-Dec-2022
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  • 63.75
  • 64.00
  • 63.05
  • 63.10
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  166071
  •  105.64
  •  94.48
  •  56.01

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 1,381.50
  • N/A
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 1,376.46
  • N/A
  • 3.04

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 64.98%
  • 2.52%
  • 27.37%
  • FII
  • DII
  • Others
  • 0.48%
  • 0.01%
  • 4.64%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -26.52
  • -54.77
  • -6.34

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 1.10

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 8.99

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 25.86
  • 4.15
  • -

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 8.30
  • 10.11
  • 14.06

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.09
  • 1.87
  • -6.92

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 22
Sep 21
Var%
Jun 22
Jun 21
Var%
Mar 22
Mar 21
Var%
Dec 21
Dec 20
Var%
Net Sales
4.39
1.18
272.03%
3.54
2.01
76.12%
4.22
1.56
170.51%
4.43
1.51
193.38%
Expenses
26.09
28.80
-9.41%
24.62
44.58
-44.77%
23.94
23.14
3.46%
36.91
28.12
31.26%
EBITDA
-21.70
-27.62
-
-21.08
-42.58
-
-19.72
-21.58
-
-32.48
-26.61
-
EBIDTM
-494.62%
-2,332.60%
-595.65%
-2,122.43%
-467.09%
-1,386.19%
-732.66%
-1,758.56%
Other Income
0.21
0.50
-58.00%
0.44
0.84
-47.62%
0.12
1.32
-90.91%
0.14
1.62
-91.36%
Interest
0.07
0.15
-53.33%
0.10
0.15
-33.33%
0.10
0.24
-58.33%
0.13
0.18
-27.78%
Depreciation
1.62
1.03
57.28%
1.58
1.03
53.40%
1.10
1.07
2.80%
1.22
1.14
7.02%
PBT
-23.18
-28.30
-
-16.33
-39.21
-
-20.80
-21.57
-
-33.69
-26.30
-
Tax
0.00
0.00
0
0.00
0.00
0
0.00
0.05
-100.00%
0.00
-1.91
-
PAT
-23.18
-28.30
-
-16.33
-39.21
-
-20.80
-21.61
-
-33.69
-24.39
-
PATM
-528.42%
-2,390.12%
-461.35%
-1,954.49%
-492.73%
-1,388.18%
-759.98%
-1,612.16%
EPS
-1.47
-2.05
-
-1.03
-2.84
-
-1.32
-1.56
-
-2.44
-1.77
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 08
Mar 07
Net Sales
16.58
11.84
13.48
14.41
285.67
625.26
543.53
499.52
520.86
117.28
111.92
Net Sales Growth
164.86%
-12.17%
-6.45%
-94.96%
-54.31%
15.04%
8.81%
-4.10%
344.12%
4.79%
 
Cost Of Goods Sold
0.00
0.00
0.00
0.00
68.74
152.17
147.06
162.64
177.61
44.18
42.04
Gross Profit
16.58
11.84
13.48
14.41
216.93
473.09
396.47
336.88
343.25
73.10
69.88
GP Margin
100.00%
100%
100%
100%
75.94%
75.66%
72.94%
67.44%
65.90%
62.33%
62.44%
Total Expenditure
111.56
134.09
93.42
130.13
296.65
423.61
414.46
398.18
361.40
104.61
95.57
Power & Fuel Cost
-
0.00
0.00
1.63
19.37
33.56
31.50
29.32
28.04
7.95
6.34
% Of Sales
-
0%
0%
11.31%
6.78%
5.37%
5.80%
5.87%
5.38%
6.78%
5.66%
Employee Cost
-
21.02
18.53
17.41
36.49
61.27
52.17
35.64
31.75
12.25
9.53
% Of Sales
-
177.53%
137.46%
120.82%
12.77%
9.80%
9.60%
7.13%
6.10%
10.45%
8.52%
Manufacturing Exp.
-
108.96
71.16
103.25
147.09
144.07
153.86
139.49
95.91
29.74
27.89
% Of Sales
-
920.27%
527.89%
716.52%
51.49%
23.04%
28.31%
27.92%
18.41%
25.36%
24.92%
General & Admin Exp.
-
3.65
3.31
4.96
13.48
20.66
19.45
22.48
20.14
8.38
7.53
% Of Sales
-
30.83%
24.55%
34.42%
4.72%
3.30%
3.58%
4.50%
3.87%
7.15%
6.73%
Selling & Distn. Exp.
-
0.00
0.00
0.00
4.89
8.57
7.46
6.73
5.17
2.06
2.15
% Of Sales
-
0%
0%
0%
1.71%
1.37%
1.37%
1.35%
0.99%
1.76%
1.92%
Miscellaneous Exp.
-
0.46
0.41
2.88
6.59
3.31
2.95
1.88
2.77
0.05
2.15
% Of Sales
-
3.89%
3.04%
19.99%
2.31%
0.53%
0.54%
0.38%
0.53%
0.04%
0.09%
EBITDA
-94.98
-122.25
-79.94
-115.72
-10.98
201.65
129.07
101.34
159.46
12.67
16.35
EBITDA Margin
-572.86%
-1032.52%
-593.03%
-803.05%
-3.84%
32.25%
23.75%
20.29%
30.61%
10.80%
14.61%
Other Income
0.91
5.32
7.75
14.04
27.25
23.27
21.09
19.62
8.58
3.18
1.46
Interest
0.40
0.67
0.94
0.55
1.91
4.63
5.68
5.88
4.71
5.06
3.03
Depreciation
5.52
4.39
4.35
4.17
14.20
24.76
21.41
17.50
11.78
4.44
4.01
PBT
-94.00
-122.00
-77.47
-106.40
0.16
195.53
123.07
97.58
151.55
6.36
10.76
Tax
0.00
0.00
-5.32
-12.18
24.06
71.84
35.88
25.74
42.80
-1.99
-0.51
Tax Rate
0.00%
0.00%
6.87%
11.45%
15037.50%
36.74%
29.15%
26.38%
28.24%
-31.29%
-4.74%
PAT
-94.00
-122.00
-72.15
-94.22
-23.90
123.69
87.19
71.85
108.75
8.35
11.26
PAT before Minority Interest
-94.00
-122.00
-72.15
-94.22
-23.90
123.69
87.19
71.85
108.75
8.35
11.26
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
-566.95%
-1030.41%
-535.24%
-653.85%
-8.37%
19.78%
16.04%
14.38%
20.88%
7.12%
10.06%
PAT Growth
0.00%
-
-
-
-
41.86%
21.35%
-33.93%
1,202.40%
-25.84%
 
EPS
-6.46
-8.39
-4.96
-6.48
-1.64
8.51
6.00
4.94
7.48
0.57
0.77

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 08
Mar 07
Shareholder's Funds
96.15
108.01
143.35
239.13
767.41
667.00
595.28
559.31
106.39
101.52
Share Capital
14.54
12.73
12.73
12.73
12.73
12.73
12.73
12.73
11.57
5.76
Total Reserves
81.61
58.36
130.62
226.40
754.68
654.27
582.56
546.59
94.82
95.76
Non-Current Liabilities
3.57
4.50
12.07
24.51
30.20
28.21
40.54
86.43
57.06
46.78
Secured Loans
0.00
0.00
0.00
0.00
0.25
22.65
37.08
55.09
54.62
41.49
Unsecured Loans
0.00
0.39
1.08
1.78
1.98
3.29
4.56
6.36
0.00
0.00
Long Term Provisions
2.00
1.73
1.72
1.49
3.69
2.84
2.39
2.27
0.00
0.00
Current Liabilities
102.21
109.81
120.03
156.97
225.83
208.05
210.62
127.39
35.08
24.95
Trade Payables
1.99
3.00
5.78
7.09
56.82
37.94
35.60
43.89
20.14
11.87
Other Current Liabilities
5.44
12.13
20.00
32.00
29.43
46.14
48.18
42.45
0.63
1.06
Short Term Borrowings
0.00
0.00
0.00
0.00
30.57
30.49
24.16
28.24
0.00
0.00
Short Term Provisions
94.78
94.68
94.25
117.88
109.01
93.49
102.68
12.81
14.32
12.02
Total Liabilities
201.93
222.32
275.45
420.61
1,023.44
903.26
846.44
773.13
198.53
173.25
Net Block
37.56
20.96
24.69
22.35
307.73
305.72
305.35
171.95
109.77
95.62
Gross Block
83.40
66.95
77.11
39.48
375.68
348.92
325.15
290.52
141.20
120.47
Accumulated Depreciation
45.83
45.99
52.42
17.13
67.95
43.19
19.80
118.57
31.43
24.86
Non Current Assets
41.44
25.74
115.95
22.37
349.61
322.10
318.79
291.31
115.72
105.60
Capital Work in Progress
3.55
4.77
0.00
0.02
24.74
9.72
7.20
107.01
3.66
5.02
Non Current Investment
0.00
0.00
0.00
0.00
0.07
0.07
0.07
0.00
2.29
4.96
Long Term Loans & Adv.
0.33
0.00
91.25
0.00
16.86
6.39
6.16
10.89
0.00
0.00
Other Non Current Assets
0.00
0.00
0.00
0.00
0.20
0.20
0.00
1.46
0.00
0.00
Current Assets
160.49
196.58
159.50
398.24
673.83
581.16
527.66
476.98
82.79
67.60
Current Investments
45.16
0.09
0.05
222.93
278.73
300.89
0.05
0.04
0.00
0.00
Inventories
0.02
0.14
0.00
0.00
139.47
92.51
83.46
81.81
24.40
22.90
Sundry Debtors
1.30
1.76
2.27
2.64
61.54
45.83
53.56
40.17
35.59
16.14
Cash & Bank
5.52
46.65
15.09
0.69
28.22
9.17
241.40
279.69
3.04
9.78
Other Current Assets
108.49
6.69
1.37
2.78
165.88
132.76
149.18
75.28
19.77
18.79
Short Term Loans & Adv.
99.78
141.25
140.72
169.20
115.53
99.87
108.96
34.06
14.93
14.33
Net Current Assets
58.28
86.77
39.48
241.27
448.00
373.11
317.04
349.59
47.71
42.65
Total Assets
201.93
222.32
275.45
420.61
1,023.44
903.26
846.45
773.14
198.53
173.24

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 08
Mar 07
Mar 06
Cash From Operating Activity
-127.54
-96.02
-134.57
-52.61
69.94
109.17
67.50
3.94
16.24
5.51
PBT
-122.00
-77.47
-106.40
0.16
195.53
123.07
97.58
6.36
10.76
6.49
Adjustment
-1.09
-2.70
-8.26
-4.87
10.32
12.91
10.98
11.22
6.54
6.56
Changes in Working Capital
-3.93
-14.70
-17.13
-32.98
-92.37
7.90
-14.36
-12.96
0.46
-6.52
Cash after chg. in Working capital
-127.02
-94.88
-131.79
-37.70
113.47
143.88
94.20
4.63
17.75
6.54
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-0.52
-1.15
-2.78
-14.92
-43.54
-34.71
-26.70
-0.69
-1.51
-1.03
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-22.23
55.84
146.22
37.13
-0.61
-310.64
-38.63
-16.20
-20.46
-9.45
Net Fixed Assets
-15.23
5.39
-37.61
360.92
-41.78
-26.29
-187.49
-19.37
-21.18
-13.51
Net Investments
-130.73
-53.26
117.43
21.74
-15.06
-342.87
-14.91
2.67
-0.87
4.00
Others
123.73
103.71
66.40
-345.53
56.23
58.52
163.77
0.50
1.59
0.06
Cash from Financing Activity
145.69
34.86
2.81
4.53
-52.07
-30.39
-68.07
5.52
12.62
2.73
Net Cash Inflow / Outflow
-4.07
-5.33
14.45
-10.94
17.26
-231.86
-39.20
-6.74
8.40
-1.20
Opening Cash & Equivalents
9.35
14.68
0.23
17.89
8.69
240.55
279.75
9.78
1.37
2.57
Closing Cash & Equivalent
5.27
9.35
14.68
0.23
25.95
8.69
240.55
3.04
9.78
1.37

Financial Ratios

Consolidated /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 08
Mar 07
Book Value (Rs.)
6.09
5.15
11.26
18.79
60.29
52.40
46.77
43.56
9.19
35.21
ROA
-57.51%
-28.99%
-27.07%
-3.31%
12.84%
9.97%
8.87%
22.38%
4.49%
7.12%
ROE
-145.90%
-67.29%
-49.27%
-4.75%
17.25%
13.81%
12.50%
32.91%
8.04%
11.76%
ROCE
-117.81%
-60.09%
-54.67%
0.40%
26.01%
18.19%
15.43%
37.93%
7.51%
10.74%
Fixed Asset Turnover
0.16
0.19
0.25
1.38
1.73
1.62
1.63
2.42
0.92
1.02
Receivable days
47.15
54.60
62.22
41.00
31.34
33.32
34.19
26.51
78.68
50.16
Inventory Days
2.53
3.83
0.00
0.00
67.71
58.98
60.29
37.16
71.95
73.54
Payable days
0.00
0.00
18.53
39.04
38.79
33.17
35.72
32.74
57.23
45.77
Cash Conversion Cycle
49.67
58.43
43.70
1.96
60.26
59.13
58.77
30.93
93.40
77.93
Total Debt/Equity
0.01
0.02
0.01
0.01
0.04
0.11
0.14
0.20
0.51
0.41
Interest Cover
-181.00
-81.35
-191.96
1.08
43.25
22.65
17.61
33.18
2.26
4.55

News Update:


  • Suven Life Sciences randomizes first patient in phase-3 global clinical trial of Masupirdine
    17th Nov 2022, 11:59 AM

    The trial is a multicenter, randomized, double-blind, placebo-controlled study planned across 50 sites in the North America and Europe

    Read More
  • Suven Life Sciences - Quarterly Results
    10th Nov 2022, 17:14 PM

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.